HES6 and prostate neoplasm: In this model, we predict that i) HES5 expression in benign epithelial cells contributes to HES6 repression and ii) HES5 promoter methylation and silencing in prostate tumours potentiates AR activation of HES6 to start an oncogenic feed-forward transcriptional signalling network (Fig. 3j).